e-learning
resources
ERJ
2013
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension
Savale Laurent, Magnier Romain, Le Pavec Jérôme, Jaïs Xavier, Montani David, O'Callaghan Dermot S., Humbert Marc, Dingemanse Jasper, Simonneau Gérald, Sitbon Olivier
Source:
Eur Respir J 2013; 41: 96-103
Journal Issue:
January
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Savale Laurent, Magnier Romain, Le Pavec Jérôme, Jaïs Xavier, Montani David, O'Callaghan Dermot S., Humbert Marc, Dingemanse Jasper, Simonneau Gérald, Sitbon Olivier. Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension. Eur Respir J 2013; 41: 96-103
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The definition of pulmonary hypertension: history, practical implications and current controversies
Should we screen for hereditary pulmonary hypertension?
Patient with ankylosing spondylitis and pulmonary hypertension
Related content which might interest you:
Bosentan therapy for portopulmonary hypertension
Source: Eur Respir J 2005; 25: 502-508
Year: 2005
Experience with inhaled iloprost and bosentan in portopulmonary hypertension
Source: Eur Respir J 2007; 30: 1096-1102
Year: 2007
Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension
Source: Eur Respir J 2004; 24: 1007-1010
Year: 2004
Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension
Source: Eur Respir J 2009; 33: 92-98
Year: 2009
Survival with first-line bosentan in patients with primary pulmonary hypertension
Source: Eur Respir J 2005; 25: 244-249
Year: 2005
Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2
Source: Eur Respir J 2004; 24: 353-359
Year: 2004
Goal-oriented treatment and combination therapy for pulmonary arterial hypertension
Source: Eur Respir J 2005; 26: 858-863
Year: 2005
Sildenafil treatment for portopulmonary hypertension
Source: Eur Respir J 2006; 28: 563-567
Year: 2006
Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension
Source: Eur Respir J 2006 Oct 01;28(4):691-694
Year: 2006
Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension
Source: Eur Respir J 2007; 29: 469-475
Year: 2007
Bosentan does not improve pulmonary hypertension and lung remodeling in heart failure
Source: Eur Respir J 2011; 37: 578-586
Year: 2011
Pulmonary hypertension in COPD
Source: Eur Respir Mon 2013; 59: 189-205
Year: 2013
Ambrisentan for therapy of portopulmonary hypertension (POPH): Update on safety and efficacy
Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments
Year: 2012
Sitaxsentan treatment for patients with pulmonary arterial hypertension (PAH) failing bosentan due to lack of efficacy
Source: Eur Respir J 2005; 26: Suppl. 49, 476s
Year: 2005
Successful transition from oral prostacyclin analogue (beraprost) to the selective endothelin receptor antagonist (sitaxsentan) therapy in pulmonary arterial hypertension
Source: Annual Congress 2007 - Pulmonary hypertension: diagnosis and treatment
Year: 2007
Current medical therapies in pulmonary arterial hypertension
Source: Eur Respir Mon 2012; 57: 26-41
Year: 2012
Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment
Source: Eur Respir J 2011; 38: 851-860
Year: 2011
The new clinical trials on pharmacological treatment in pulmonary arterial hypertension
Source: Eur Respir J 2002; 20: 1037-1049
Year: 2002
The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study
Source: Eur Respir J 2006; 28: 138-143
Year: 2006
Effects of endothelin receptor antagonist (ERA) bosentan on myocardial glucose metabolism in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH)
Source: International Congress 2017 – PAH and CTEPH
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept